From bench to clinic: the development of VLA1553/IXCHIQ, a live-attenuated chikungunya vaccine.

ABSTRACT:

Background

Over the past 20 years, over 5 million cases of chikungunya, a mosquito-transmitted viral disease, have been reported in over 110 countries. Until recently, preventative strategies for chikungunya were largely ineffective, relying on vector control and individual avoidance of mosquito bites.

Methods

This review outlines the preclinical and clinical efficacy and safety data that led to the approval of VLA1553 (IXCHIQ®), a live-attenuated vaccine against chikungunya disease. It also describes the innovative development pathway of VLA1553, based on an immunological surrogate of protection, and discusses ongoing and future post-licensure studies.

Results

In mice and non-human primate models, VLA1553 elicited high titres of neutralizing antibodies, conferred pro

SUBMITTER: Chen LH 

PROVIDER: S-EPMC11497415 | biostudies-literature | 2024 Oct

REPOSITORIES: biostudies-literature